We therefore propose that the development of therapies aiming at inactivating/inhibiting Arx in α-cells could potentially open new avenues for diabetes research and/or aid the design of efficient β-cell differentiation protocols in the context of stem cell research. This evidence concerns the gene ARX and diabetes mellitus.